BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Liver
,
Pharmacogenetics
,
Acetaminophen
,
rs3825942
,
FABP1
,
cell-cell adhesion
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
E bx
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
Drosophila wild type, Nurf301 and hop[Tum-1] mutant third instar larvae
Explore Curated Studies Results
Literature
Most Relevant Literature
NURF301 contributes to gypsy chromatin insulator-mediated nuclear organization.
Effect of Nrf2 loss on senescence and cognition of tau-based P301S mice.
Spreading of P301S Aggregated Tau Investigated in Organotypic Mouse Brain Slice Cultures.
Mice expressing P301S mutant human tau have deficits in interval timing.
Complement C3a receptor antagonist alleviates tau pathology and ameliorates cognitive deficits in P3…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
The Study of the BX Velocity Stent in the Treatment of De Novo Artery Lesions.
FIM-BR - First-in-Man Study (Brazil Part) With Sirolimus-Coated BX VELOCITY Stent
Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems
The Study of the BX VELOCITY Stent In Patients With De Novo Coronary Artery Lesions.
FIM-NL - First-in-Man Study (Netherlands Part) With Sirolimus Coated Modified BX Velocity Stent
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ